Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease
- PMID: 17285785
- DOI: 10.4065/82.1.48
Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease
Abstract
Objective: To examine the frequency and spectrum of diseases associated with isolated reduction in the diffusing capacity of lung for carbon monoxide (D(Lco)).
Patients and methods: We retrospectively identified all potentially dyspneic patients who had pulmonary function tests (PFTs) performed at the Mayo Clinic in Jacksonville, Fla, between January 1, 1990, and June 30, 2000, that showed reduced D(Lco) (< 70% of predicted), normal lung volumes (total lung capacity and residual volume > 80% and < 120% of predicted, respectively), and airflow variables (forced expiratory volume in 1 second and forced vital capacity values > 80% of predicted and forced expiratory volume in 1 second/forced vital capacity ratio > 70% of predicted). Only patients who had also undergone chest computed tomography (CT) and echocardiography within 1 month of PFTs were studied.
Results: Of the 38,095 patients who underwent PFTs during the study period, 179 (0.47%; 95% confidence interval [CI], 0.40%-0.54%) had isolated D(Lco) abnormalities. The 27 patients (15.1%; 95% CI, 10.2%-21.2%) who had also undergone chest CT and echocardiography within 1 month of PFTs form the study cohort reported herein. Their mean D(Lco) was 50% +/- 15% (95% CI, 45%-56%) with average normal pulse oxygen saturation at rest and mild hypoxemia with activity. Thirteen of the 27 patients (48%; 95% CI, 28.7%-68.1%) had underlying emphysema evident on CT. Eleven of these 13 patients had emphysema associated with a restrictive lung process. The 14 patients without emphysema had interstitial lung disease, pulmonary vascular disease, and other isolated findings. Six patients with combined emphysema and idiopathic pulmonary fibrosis accounted for the largest percentage (22%) of patients with Isolated D(Lco) reduction. The mean +/- SD smoking history of the 27 patients in the study cohort was 36 +/- 33 pack-years (range, 0-116 pack-years).
Conclusion: Dyspneic patients with respiratory symptoms and normal lung volumes and airflows associated with Isolated reduction in D(Lco) should be evaluated for underlying diseases such as emphysema, with or without a concomitant restrictive process, and pulmonary vascular disease.
Similar articles
-
Diffusing capacity for carbon monoxide correlates best with tissue volume from quantitative CT scanning analysis.Chest. 2015 Jun;147(6):1485-1493. doi: 10.1378/chest.14-1693. Chest. 2015. PMID: 25500912
-
Early emphysematous changes in asymptomatic smokers: detection with 3He MR imaging.Radiology. 2006 Jun;239(3):875-83. doi: 10.1148/radiol.2393050111. Radiology. 2006. PMID: 16714465
-
[Role of single-breath carbon monoxide-diffusing capacity in monitoring the bleomycin-induced lung toxicity in human].Zhonghua Nei Ke Za Zhi. 2003 Oct;42(10):709-12. Zhonghua Nei Ke Za Zhi. 2003. PMID: 14633466 Chinese.
-
Pulmonary hypertension in chronic lung diseases.J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D109-16. doi: 10.1016/j.jacc.2013.10.036. J Am Coll Cardiol. 2013. PMID: 24355635 Review.
-
Combined Pulmonary Fibrosis and Emphysema: Pulmonary Function Testing and a Pathophysiology Perspective.Medicina (Kaunas). 2019 Sep 10;55(9):580. doi: 10.3390/medicina55090580. Medicina (Kaunas). 2019. PMID: 31509942 Free PMC article. Review.
Cited by
-
Quantitative evaluation of disease severity in connective tissue disease-associated interstitial lung disease by dual-energy computed tomography.Respir Res. 2022 Mar 5;23(1):47. doi: 10.1186/s12931-022-01972-4. Respir Res. 2022. PMID: 35248040 Free PMC article.
-
Chronic Obstructive Pulmonary Disease Combined with Interstitial Lung Disease.Tuberc Respir Dis (Seoul). 2022 Apr;85(2):122-136. doi: 10.4046/trd.2021.0141. Epub 2022 Jan 27. Tuberc Respir Dis (Seoul). 2022. PMID: 35385639 Free PMC article. Review.
-
Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis.Respir Res. 2022 Jun 21;23(1):164. doi: 10.1186/s12931-022-02082-x. Respir Res. 2022. PMID: 35729565 Free PMC article.
-
Combined pulmonary fibrosis and emphysema syndrome: a review.Chest. 2012 Jan;141(1):222-231. doi: 10.1378/chest.11-1062. Chest. 2012. PMID: 22215830 Free PMC article. Review.
-
Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement.Am J Respir Crit Care Med. 2022 Aug 15;206(4):e7-e41. doi: 10.1164/rccm.202206-1041ST. Am J Respir Crit Care Med. 2022. PMID: 35969190 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical